Pharmaceutical, health two enterprises to study the market to seek new breakthroughs in marketing
Release time:
2020-08-14
Pharmaceutical and Health Enterprises Research Markets Seek New Breakthroughs in Marketing
News 5# July 12 and 15 , Peak Health Technology Company and Peak Pharmaceutical Company successively held special marketing conferences to analyze the shortcomings in marketing work, study and explore marketing innovation ways and seek breakthroughs.
5 12 held the marketing meeting of Jianfeng Health Technology Company, according to the existing three major business sectors of health food, plant extracts and Chinese herbal pieces, with key products and channel sales as the main topics for summary analysis, exchange, study and discussion. Jin Wenwei, manager of the marketing center of Health Technology Company, summarized the sales situation in the first four months of this year and planned the next specific work according to the sales situation. Chen Daiyou, general manager of Health Technology Company, discussed at the meeting such issues as "what are our products", "where are our customers", "how to find our customers" and "how do we do it now". According to the attribute differences of the three major categories of products involved in the sales business and the diversity of sales channels, detailed analysis and elaboration were carried out to clarify the sales focus and direction and unify the thinking to reach a consensus. At the
meeting, the health technology company discussed and mobilized to restart Jinhua terminal sales mode. with the support of the group company's resources, it plans to select health food gu tai capsule based on traditional Chinese medicine prescription as a breakthrough point to break the sluggish situation of existing terminal sales. Reasonably match and improve Jinhua terminal team, tap internal potential, promote market personnel to enter the terminal front line and contact the market frontier information, on the basis of the original terminal business to make greater progress, do everything possible to do sales performance. Chen Daiyou hopes that all marketing staff will build up confidence to meet sales challenges, adhere to the combination of "going out" and "inviting in", strengthen internal experience sharing and exchange, strengthen business knowledge learning, improve the subjective initiative of sales staff, and further extend marketing work to the depth of the market. Health technology companies will also focus on the construction and cultivation of sales teams, and the corresponding sales management system and job responsibilities will be continuously refined and launched one after another.
5 April 15 , the management teams of marketing units such as Jianfeng Pharmacy, Jinhua Pharmaceutical Company and Pharmaceutical Sales Company gathered together to summarize and analyze the problems existing in the marketing work and deploy the next work priorities. The heads of the three marketing units successively reported on the completion of the sales work in the first four months, focusing on analyzing the existing deficiencies and problems faced, and putting forward improvement ideas and work arrangements for the next step. Jin Xuecai, deputy general manager in charge of sales of the pharmaceutical company, put forward work requirements from the aspects of sales model innovation, retail market growth, slow insurance consultation and so on.
Chairman of the Group Company and Chairman of the Pharmaceutical Company Jiang Xiaomeng attended the meeting. He hoped that the pharmaceutical company team would further strengthen its study and make great efforts to innovate marketing models and marketing methods. According to the current market situation, he asked drug retail to expand its own chain and improve the assessment mode of pharmacies; commercial sales should clarify the working ideas and introduce relevant policies to stimulate market vitality in view of the new pharmaceutical policies such as the "two-vote system"; industrial sales should strictly clarify post responsibilities, give marketing personnel greater autonomy, put an end to illegal sales, and strengthen incentive and assessment. At the same time, pharmaceutical companies are required to increase their support for marketing model innovation and build a platform for employees to fully display their talents, so as to stimulate the enthusiasm and initiative of marketing personnel and achieve breakthroughs in marketing performance. (Xu Yuting Ni Yingzhen)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page